"Rifamycins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of ANTI-BACTERIAL AGENTS characterized by a chromophoric naphthohydroquinone group spanned by an aliphatic bridge not previously found in other known ANTI-BACTERIAL AGENTS. They have been isolated from fermentation broths of Streptomyces mediterranei.
| Descriptor ID |
D012294
|
| MeSH Number(s) |
D03.633.400.811 D04.345.295.750
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Rifamycins".
Below are MeSH descriptors whose meaning is more specific than "Rifamycins".
This graph shows the total number of publications written about "Rifamycins" by people in this website by year, and whether "Rifamycins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2005 | 4 | 0 | 4 |
| 2006 | 2 | 1 | 3 |
| 2007 | 2 | 0 | 2 |
| 2008 | 1 | 0 | 1 |
| 2009 | 2 | 0 | 2 |
| 2010 | 4 | 1 | 5 |
| 2011 | 2 | 0 | 2 |
| 2013 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Rifamycins" by people in Profiles.
-
The potential for development of clinically relevant microbial resistance to rifaximin-a: a narrative review. Clin Microbiol Rev. 2023 12 20; 36(4):e0003923.
-
Development of a new travellers' diarrhoea clinical severity classification and its utility in confirming rifamycin-SV efficacy. J Travel Med. 2023 10 31; 30(6).
-
Childhood tuberculosis. Curr Opin Infect Dis. 2022 10 01; 35(5):477-483.
-
Rifamycin SV-MMX? as the recommended self-treatment for moderate to severe travellers' diarrhoea: reply. J Travel Med. 2019 05 10; 26(3).
-
New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases. Dig Liver Dis. 2018 08; 50(8):741-749.
-
Rifamycin SV-MMX? for treatment of travellers' diarrhea: equally effective as ciprofloxacin and not associated with the acquisition of multi-drug resistant bacteria. J Travel Med. 2018 01 01; 25(1).
-
Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017 Oct; 29(10):1109-1117.
-
Antimicrobial Susceptibility of Staphylococcus Isolates from the Skin of Patients with Diarrhea-Predominant Irritable Bowel Syndrome Treated with Repeat Courses of Rifaximin. Antimicrob Agents Chemother. 2017 01; 61(1).
-
Prospective Multicenter Observational Study of Overt Hepatic Encephalopathy. Dig Dis Sci. 2016 06; 61(6):1728-34.
-
Therapeutic Effects and Mechanisms of Action of Rifaximin in Gastrointestinal Diseases. Mayo Clin Proc. 2015 Aug; 90(8):1116-24.